UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 389

Sortiert nach

Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2020-01, Vol.31 (1), p.17-29

2020

Link zum Volltext

Verfügbarkeit prüfen

Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2013-10, Vol.24 Suppl 6, p.vi144-vi148

2013

Link zum Volltext

Verfügbarkeit prüfen

EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT

Gut, 2011-06, Vol.60 (6), p.747-758

2011

Link zum Volltext

Verfügbarkeit prüfen

Localised Synovial Sarcoma in Adolescents and Young Adults Versus Adults – Is There a Difference in Outcome?

Clinical oncology (Royal College of Radiologists (Great Britain)), 2023-03, Vol.35 (3), p.e256-e262

2023

Link zum Volltext

Verfügbarkeit prüfen

T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma

Leukemia, 2005-04, Vol.19 (4), p.652-658

2005

Link zum Volltext

Verfügbarkeit prüfen

Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma

Leukemia, 2006-02, Vol.20 (2), p.313-318

2006

Link zum Volltext

Verfügbarkeit prüfen

Palliative chemotherapy for advanced gastric cancer

Annals of oncology, 2004-11, Vol.15 (11), p.1585-1595

2004

Link zum Volltext

Verfügbarkeit prüfen

Real-World Data for Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer (RELEVANT): A Retrospective Multicentric Analysis of Clinical Practice in Austria

International journal of endocrinology, 2020, Vol.2020, p.8834148-8

2020

Link zum Volltext

Verfügbarkeit prüfen

Corrigendum to “Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”: [Annals of Oncology 31 (2020) 17–29]

Annals of oncology, 2023-03, Vol.34 (3), p.325-325

2023

Link zum Volltext

Verfügbarkeit prüfen

High-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial

Annals of oncology, 2015-08, Vol.26 (8), p.1760-1765

2015

Link zum Volltext

Verfügbarkeit prüfen

ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0

Annals of oncology, 2023-09, Vol.34 (9), p.734-771

2023

Link zum Volltext

Verfügbarkeit prüfen

Successful antibiotic treatment of Helicobacter pylori negative gastric mucosa associated lymphoid tissue lymphomas

Gut, 2006-05, Vol.55 (5), p.616-618

2006

Link zum Volltext

Verfügbarkeit prüfen

Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites

Leukemia, 2004-10, Vol.18 (10), p.1722-1726

2004

Link zum Volltext

Verfügbarkeit prüfen

How I treat medullary thyroid cancer

ESMO open, 2021-06, Vol.6 (3), p.100183-100183, Article 100183

2021

Link zum Volltext

Verfügbarkeit prüfen

Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib

Leukemia, 2017-05, Vol.31 (5), p.1117-1122

2017

Link zum Volltext

Verfügbarkeit prüfen

18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading

Annals of oncology, 2006-05, Vol.17 (5), p.780-784

2006

Link zum Volltext

Verfügbarkeit prüfen

Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be managed safely by a watch and wait strategy: experience from a large international series

Gut, 2007-12, Vol.56 (12), p.1685-1687

2007

Link zum Volltext

Verfügbarkeit prüfen

Pulmonary neuroendocrine tumours and somatostatin receptor status: an assessment of unlicensed use of somatostatin analogues in the clinical practice

ESMO open, 2022-06, Vol.7 (3), p.100478-100478, Article 100478

2022

Link zum Volltext

Verfügbarkeit prüfen

DEPTH OF REMISSION FOLLOWING FIRST LINE HP‐ERADICATION IS AN INDEPENDENT PROGNOSTIC FACTOR IN GASTRIC MALT LYMPHOMA

Hematological oncology, 2019-06, Vol.37 (S2), p.263-263

2019

Link zum Volltext

Verfügbarkeit prüfen

Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx)

Annals of oncology, 2018-10, Vol.29, p.viii467-viii468

2018

Link zum Volltext

Verfügbarkeit prüfen

Sex-differences in [68Ga]Ga-DOTANOC biodistribution

Nuclear medicine and biology, 2019-09, Vol.76-77, p.15-20

2019

Link zum Volltext

Verfügbarkeit prüfen

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma

Blood, 2004-10, Vol.104 (8), p.2269-2271

2004

Link zum Volltext

Verfügbarkeit prüfen

Final overall survival results of frontline bortezomib plus rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) vs R-CHOP in transplantation-ineligible patients (pts) with newly diagnosed mantle-cell lymphoma (MCL): A randomized, open-label, phase III (LYM-3002) study

Annals of oncology, 2018-10, Vol.29, p.viii359-viii359

2018

Link zum Volltext

Verfügbarkeit prüfen

Prevalence of anxiety and depression in people with different types of cancer or haematologic malignancies: a cross-sectional study

Epidemiology and psychiatric sciences, 2022-01, Vol.31, p.e74-e74, Article e74

2022

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of lenvatinib in patients with advanced pancreatic (panNETs) and gastrointestinal (giNETs) grade 1/2 (G1/G2) neuroendocrine tumors: Results of the international phase II TALENT trial (GETNE 1509)

Annals of oncology, 2018-10, Vol.29, p.viii467-viii467

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 389

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(364)
Mit Volltextzugriff
(354)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(235)
Science & Technology
(229)
Life Sciences & Biomedicine
(227)
Biological And Medical Sciences
(154)
Female
(154)
Medical Sciences
(151)
Male
(149)
Middle Aged
(145)
Oncology
(137)
Aged
(135)
Adult
(101)
Chemotherapy
(71)
Pharmacology. Drug Treatments
(64)
Treatment Outcome
(58)
Antineoplastic Agents
(54)
Aged, 80 And Over
(51)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(50)
Hematology
(50)
Hematologic And Hematopoietic Diseases
(46)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(46)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT

Localised Synovial Sarcoma in Adolescents and Young Adults Versus Adults – Is There a Difference in Outcome?

T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma

Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma

Palliative chemotherapy for advanced gastric cancer

Real-World Data for Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer (RELEVANT): A Retrospective Multicentric Analysis of Clinical Practice in Austria

Corrigendum to “Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”: [Annals of Oncology 31 (2020) 17–29]

High-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial

ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0

Successful antibiotic treatment of Helicobacter pylori negative gastric mucosa associated lymphoid tissue lymphomas

Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites

How I treat medullary thyroid cancer

Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib

18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading

Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be managed safely by a watch and wait strategy: experience from a large international series

Pulmonary neuroendocrine tumours and somatostatin receptor status: an assessment of unlicensed use of somatostatin analogues in the clinical practice

DEPTH OF REMISSION FOLLOWING FIRST LINE HP‐ERADICATION IS AN INDEPENDENT PROGNOSTIC FACTOR IN GASTRIC MALT LYMPHOMA

Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx)

Sex-differences in [68Ga]Ga-DOTANOC biodistribution

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma

Final overall survival results of frontline bortezomib plus rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) vs R-CHOP in transplantation-ineligible patients (pts) with newly diagnosed mantle-cell lymphoma (MCL): A randomized, open-label, phase III (LYM-3002) study

Prevalence of anxiety and depression in people with different types of cancer or haematologic malignancies: a cross-sectional study

Efficacy of lenvatinib in patients with advanced pancreatic (panNETs) and gastrointestinal (giNETs) grade 1/2 (G1/G2) neuroendocrine tumors: Results of the international phase II TALENT trial (GETNE 1509)

Suchergebnisse filtern